MIMETAS
MIMETAS strives to contribute to groundbreaking therapies with unique human disease biology, revealed by robust, screenable assays in the most versatile technology platform. By combining technological strengths and expertise, they establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases.
Latest Content
Industry Insight
Enhancing Drug Screening With Human-Relevant Models
In this interview, Sebastiaan J. Trietsch, Chief Technology Officer at MIMETAS, discusses how microphysiological systems are advancing drug discovery through scalable human-relevant models and AI integration.
Product News
MIMETAS Launches OrganoPlate UniFlow Technology at SLAS 2025
MIMETAS, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research.
Whitepaper
Transforming Cancer Drug Discovery With Comprehensive Tumor Models
This whitepaper explores groundbreaking organ-on-a-chip technology and 3D tissue modeling that is closing the translational gap in cancer drug discovery.
Product News
MIMETAS Launches Ready-To-Use 3D Adult Stem Cell Organoid Tubules
MIMETAS announces that it has launched its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format.
Advertisement
